Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Basilea Pharmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Product Name : Cresemba
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Isavuconazonium Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Basilea Pharmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Details : Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.
Product Name : AK1780
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
January 29, 2021
Reset All
